{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:56:51Z","timestamp":1793973411513,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jhep.2023.07.026","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T11:12:53Z","timestamp":1690629173000},"page":"1139-1149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection"],"prefix":"10.1016","volume":"79","author":[{"given":"Edward J.","family":"Gane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien Huey","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2926-8671","authenticated-orcid":false,"given":"Pisit","family":"Tangkijvanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9128-3610","authenticated-orcid":false,"given":"Jung-Hwan","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-0974","authenticated-orcid":false,"given":"William","family":"Sievert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5065-9397","authenticated-orcid":false,"given":"Wattana","family":"Sukeepaisarnjaroen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedran","family":"Pavlovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3021-0821","authenticated-orcid":false,"given":"Bernadette","family":"Surujbally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3991-999X","authenticated-orcid":false,"given":"Cynthia","family":"Wat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardean E.","family":"Achneck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2023.07.026_bib1","series-title":"Global hepatitis report","year":"2017"},{"key":"10.1016\/j.jhep.2023.07.026_bib2","series-title":"Hepatitis B","year":"2021"},{"key":"10.1016\/j.jhep.2023.07.026_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.07.026_bib4","article-title":"Rebound of HBV DNA after cessation of nucleos\/tide analogues in chronic hepatitis B patients with undetectable covalently closed","volume":"2","author":"Lai","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2023.07.026_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78001-1","article-title":"Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients","volume":"10","author":"Lebosse","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.07.026_bib6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5501\/wjv.v11.i1.57","article-title":"Chronic hepatitis B: new potential therapeutic drugs target","volume":"11","author":"Leowattana","year":"2022","journal-title":"World J Virol"},{"key":"10.1016\/j.jhep.2023.07.026_bib7","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.026_bib8","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41598-020-58870-2","article-title":"Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2023.07.026_bib9","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/hep.31920","article-title":"Clinical study of single-stranded oligonucleotide RO7062931 in healthy volunteers and patients with chronic hepatitis B","volume":"74","author":"Gane","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.026_bib10","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cgh.2020.05.041","article-title":"Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis","volume":"19","author":"Anderson","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.07.026_bib11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.026_bib12","series-title":"Guidance document. Chronic hepatitis B virus infection: developing drugs for treatment","year":"2022"},{"key":"10.1016\/j.jhep.2023.07.026_bib13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2468-1253(18)30007-4","article-title":"Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand","volume":"3","author":"Maini","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.07.026_bib14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(double dagger)","volume":"72","author":"Cornberg","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.026_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105864","article-title":"GalNAc-siRNA conjugates: prospective tools on the frontier of anti-viral therapeutics","volume":"173","author":"Thangamani","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jhep.2023.07.026_bib16","series-title":"Dicerna 2020 virtual R&D update: nedosiran, RG6346 and going beyond GalXC\u2122","year":"2020"},{"key":"10.1016\/j.jhep.2023.07.026_bib17","article-title":"Insights into hepatitis B virus DNA integration-55 years after virus discovery","volume":"1","author":"Zhao","year":"2020","journal-title":"Innovation (N Y)"},{"key":"10.1016\/j.jhep.2023.07.026_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jhep.2023.07.026_bib19","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2023.07.026_bib20","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jhep.2023.07.026_bib21","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1440-1746.2011.06695.x","article-title":"Natural history of chronic hepatitis B REVEALed","volume":"26","author":"Chen","year":"2011","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2023.07.026_bib22","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.07.026_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000343857","article-title":"Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy","volume":"3","author":"Kawanaka","year":"2014","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2023.07.026_bib24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2023.07.026_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/liv.12403","article-title":"HBsAg quantification: useful for monitoring natural history and treatment outcome","volume":"34","author":"Martinot-Peignoux","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2023.07.026_bib26","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.026_bib27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/jvh.13471","article-title":"Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: a meta-analysis","volume":"28","author":"Song","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2023.07.026_bib28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1053\/j.gastro.2010.04.048","article-title":"Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study","volume":"139","author":"Liu","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.07.026_bib29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2014.04.029","article-title":"The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment","volume":"61","author":"Chen","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2023.07.026_bib30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B Study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2023.07.026_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/v13040581","article-title":"RNA interference therapy for chronic hepatitis B predicts the importance of addressing viral integration when developing novel cure strategies","volume":"13","author":"Wooddell","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2023.07.026_bib32","doi-asserted-by":"crossref","first-page":"a021428","DOI":"10.1101\/cshperspect.a021428","article-title":"Immune response in hepatitis B virus infection","volume":"5","author":"Tan","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jhep.2023.07.026_bib33","first-page":"14","article-title":"HBeAg-negative\/Anti-HBe-positive chronic hepatitis B: a 40-year-old history","author":"Bonino","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2023.07.026_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.691766","article-title":"The functions of hepatitis B virus encoding proteins: viral persistence and liver pathogenesis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2023.07.026_bib35","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2023.07.026_bib36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/jvh.13223","article-title":"Liver safety assessment in clinical trials of new agents for chronic hepatitis B","volume":"27","author":"Fontana","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2023.07.026_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3350\/cmh.2017.0106","article-title":"Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?","volume":"23","author":"Heo","year":"2017","journal-title":"Clin Mol Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823050055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827823050055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:49:47Z","timestamp":1759175387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827823050055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0168827823050055"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2023.07.026","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2023.07.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}